{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:23Z","timestamp":1772165663330,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Endocrinology Division, Department of Internal Medicine of the \u201cDr. Jose Eleuterio Gonzalez\u201d University Hospital, Universidad Aut\u00f3noma de Nuevo Le\u00f3n"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Seroprevalence of anti-SARS-CoV-2 antibodies is now available in several world regions to better estimate transmission dynamics. However, to date, there is no epidemiological data regarding anti-SARS-CoV-2 prevalence in Mexico. Therefore, we aimed to determine the prevalence of anti-SARS-CoV-2 antibodies and define the clinical and demographic characteristics associated with seroprevalence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional serological survey in Ciudad Guadalupe, NL, Mexico. City government employees voluntarily participated during July 2020. Demographic and clinical characteristics were collected at the time of blood sampling to analyze the associated characteristics. IgM\/IgG antibodies were determined using a qualitative chemiluminescent immunoassay. Descriptive statistics were used for categorical and continuous variables. Statistical significance was tested using the Chi-squared test, Student\u2019s t-test and the Mann\u2013Whitney. Logistic regression models and the odds ratios (adjusted and unadjusted) were used to estimate the association of demographic and clinical characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 3,268 participants included, 193 (5.9%, 95% CI 5.1\u20136.8) tested positive for IgM\/IgG against SARS-CoV-2. Sex, city of residence, and comorbidities did not show any association with having IgM\/IgG antibodies. A total of 114 out of 193 (59.1%) subjects with a positive test were asymptomatic, and the odds of being positive were higher in those who reported symptoms of COVID-19 in the previous four weeks to the survey (OR 4.1, 95% CI 2.9\u20135.5).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is a low rate of SARS-CoV-2 infection among government employees that have continuously been working during the pandemic. Six in ten infections were asymptomatic, and seroprevalence is low and still far from herd immunity. Epidemiological surveillance and preventive measures should be mandatory.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-06550-5","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T06:08:42Z","timestamp":1629353322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5\u00a0months after pandemic arrival"],"prefix":"10.1186","volume":"21","author":[{"given":"Cristina","family":"D\u00edaz-Salazar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"S\u00e1nchez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Rodr\u00edguez-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"Camacho-Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Sald\u00edvar-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Gerardo","family":"Gonz\u00e1lez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"key":"6550_CR1","unstructured":"COVID-19 Mexico Database. National Epidemiology Center. Mexico Government. 2020. https:\/\/coronavirus.gob.mx\/datos\/#DOView. Accessed 31 Aug 2020."},{"key":"6550_CR2","unstructured":"COVID-19 Cases in Nuevo Le\u00f3n. Nuevo Le\u00f3n Health Department. 2020. https:\/\/www.nl.gob.mx\/publicaciones\/casos-de-covid-19-en-nuevo-leon. Accessed 31 Aug 2020."},{"issue":"5","key":"6550_CR3","doi-asserted-by":"publisher","first-page":"598","DOI":"10.21149\/11606","volume":"62","author":"T Barrientos-Guti\u00e9rrez","year":"2020","unstructured":"Barrientos-Guti\u00e9rrez T, Alpuche-Aranda C, Lazcano-Ponce E, P\u00e9rez-Ferrer C, Rivera-Dommarco J. Public health in the first wave: a research agenda for cooperation under Covid-19. Salud Publica Mex. 2020;62(5):598\u2013606. https:\/\/doi.org\/10.21149\/11606.","journal-title":"Salud Publica Mex"},{"issue":"58","key":"6550_CR4","doi-asserted-by":"publisher","first-page":"2001285","DOI":"10.2807\/1560-7917.ES.2020.25.28.2001285","volume":"25","author":"B Fischer","year":"2020","unstructured":"Fischer B, Knabbe C, Vollmer T. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020. Euro Surveill. 2020;25(58):2001285. https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.28.2001285.","journal-title":"Euro Surveill"},{"issue":"10250","key":"6550_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(20)31483-5","volume":"396","author":"M Poll\u00e1n","year":"2020","unstructured":"Poll\u00e1n M, P\u00e9rez-G\u00f3mez B, Partor-Barriuso R, Oteo J, Hern\u00e1n MA, P\u00e9rez-Olmeda M. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396(10250):535\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(20)31483-5.","journal-title":"Lancet"},{"issue":"10247","key":"6550_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0140-6736(20)31304-0","volume":"396","author":"S Stringhini","year":"2020","unstructured":"Stringhini S, Wisniak A, Piumatii G, Azman A, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(20)31304-0.","journal-title":"Lancet"},{"issue":"2","key":"6550_CR7","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/ije\/dyab010","volume":"50","author":"E Bendavid","year":"2021","unstructured":"Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano R, et al. COVID-19 antibody seroprevalence in Santa Clara county. California Int J Epimeiol. 2021;50(2):410\u20139. https:\/\/doi.org\/10.1093\/ije\/dyab010.","journal-title":"California Int J Epimeiol"},{"issue":"8","key":"6550_CR8","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41591-020-0992-3","volume":"26","author":"MF Silveira","year":"2020","unstructured":"Silveira MF, Barros AJD, Horta BL, Pellanda LC, Victora GD, Dellagostin OA, et al. Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil. Nat Med. 2020;26(8):1196\u20139. https:\/\/doi.org\/10.1038\/s41591-020-0992-3.","journal-title":"Nat Med"},{"key":"6550_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.14765","author":"J Moscola","year":"2020","unstructured":"Moscola J, Sembajwe G, Jarrett M, Farber B, Chang T, McGinn T, et al. Prevalence of SARS-CoV-2 antibodies in health care personnel in the New York City area. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.14765.","journal-title":"JAMA"},{"key":"6550_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26445.10.1002\/jmv.26445","author":"R Xu","year":"2020","unstructured":"Xu R, Huang J, Duan C, Liao Q, Shan Z, Wang M, et al. Low prevalence of antibodies against SARS-CoV-2 among voluntary blood donors in Guangzhou. China J Med Virol. 2020. https:\/\/doi.org\/10.1002\/jmv.26445.10.1002\/jmv.26445.","journal-title":"China J Med Virol"},{"key":"6550_CR11","unstructured":"Data Nuevo Leon. Nuevo Leon Economy Department. Nuevo Leon Government. 2020. http:\/\/datos.nl.gob.mx\/n-l-poblacion-total-y-por-municipio\/. Accessed 26 Aug 2020."},{"key":"6550_CR12","unstructured":"Bendix Carstensen, Martyn Plummer, Esa Laara, Michael Hills. Epi: a package for statistical analysis in epidemiology. R package version 1.1.44. 2013. http:\/\/CRAN.R-project.org\/package=Epi. Accessed 8 Aug 2020."},{"key":"6550_CR13","unstructured":"Public Health Agency Sweden. F\u00f6rsta resultaten fr\u00e5n p\u00e5g\u00e5ende unders\u00f6kning av antikroppar f\u00f6r covid-19-virus. 2020. https:\/\/www.folkhalsomyndigheten.se\/nyheter-och-press\/nyhetsarkiv\/2020\/maj\/forsta-resultaten-fran-pagaende-undersokning-av-antikroppar-for-covid-19-virus. Accessed 12 Aug 2020."},{"key":"6550_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.11606\/s1518-8787.2020054002643","volume":"54","author":"L Amorim-Filho","year":"2020","unstructured":"Amorim-Filho L, Szwarcwald CL, Mateos S, Leon ACM, Medronho R, Veloso VG. Seroprevalence of IgG and IgM anti-SARS-CoV-2 among voluntary blood donors in Rio de Janeiro, Brazil. COVID-19 Global literature on coronavirus disease. Rev Saude Publica. 2020;54:69. https:\/\/doi.org\/10.11606\/s1518-8787.2020054002643.","journal-title":"Rev Saude Publica"},{"issue":"1","key":"6550_CR15","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1038\/s41467-020-17318-x","volume":"11","author":"AL Garcia-Basteiro","year":"2020","unstructured":"Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinocart C, Jim\u00e9nez A, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020;11(1):3500. https:\/\/doi.org\/10.1038\/s41467-020-17318-x.","journal-title":"Nat Commun"},{"key":"6550_CR16","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa102","author":"FJ Barrera","year":"2020","unstructured":"Barrera FJ, Shekhar S, Wurth R, Moreno-Pena PJ, Ponce OJ, Hajdenberg M, et al. Prevalence of diabetes and hypertension and their associated risks for poor outcomes in Covid-19 patients. J Endocr Soc. 2020. https:\/\/doi.org\/10.1210\/jendso\/bvaa102.","journal-title":"J Endocr Soc."},{"issue":"10250","key":"6550_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(20)31482-3","volume":"396","author":"I Eckerle","year":"2020","unstructured":"Eckerle I, Meyer B. SARS-CoV-2 seroprevalence in COVID-19 hotspots. Lancet. 2020;396(10250):514\u20135.","journal-title":"Lancet"},{"key":"6550_CR18","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.30.20047365","author":"F Wu","year":"2020","unstructured":"Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. Medrxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.30.20047365.","journal-title":"Medrxiv."},{"issue":"8","key":"6550_CR19","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","volume":"26","author":"QX Long","year":"2020","unstructured":"Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200\u20134. https:\/\/doi.org\/10.1038\/s41591-020-0965-6.","journal-title":"Nat Med"},{"issue":"10","key":"6550_CR20","doi-asserted-by":"publisher","first-page":"e01694","DOI":"10.1128\/JCM.01694-20","volume":"58","author":"P Muench","year":"2020","unstructured":"Muench P, Jochum S, Wenderoth V, Ofenloch-Haehnle B, Hombach M, Strobl A, et al. Development and validation of the elecsys Anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2. J Clin Microbiol. 2020;58(10):e01694-e1720. https:\/\/doi.org\/10.1128\/JCM.01694-20.","journal-title":"J Clin Microbiol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06550-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06550-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06550-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T06:10:56Z","timestamp":1629353456000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06550-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6550"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06550-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-84890\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,19]]},"assertion":[{"value":"10 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of the School of Medicine and \u201cDr. Jose E. Gonzalez\u201d University Hospital (EN20-00025). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"835"}}